Ben Haynor: Okay. Got it. And then obviously there’s always considerations when you’re setting terms with a distribution partner anywhere, but are there any things that we could – we should be thinking about when it comes to the potential for extending that agreement? Is it something that you guys need to see that they’re hitting the ground running and generating a lot of the sales for you guys? Would there be anything that would cause you to try and switch to another partner, or what kind of goes into a potential renewal there, to the extent you can discuss it?
Eyal Shamir: Of course, we would like to evaluate different aspects, of course. And the most important one is future sales relationship with the different societies, creating guidelines, working on the reimbursement, all the educational, staff, all the clinical support that they need to be. It’s not only sales. All the KOL support, clinical support, especially for training at the beginning. So, we will evaluate, like any other partner, all that aspect to be sure that they are delivering what we need in order to be very successful in the market.
Ben Haynor: Okay, got it. Well, that’s all I had. Thanks for taking the questions, gentlemen. Appreciate it.
Operator: . The next question is a follow up question from Kemp Dolliver of Brookline Capital Markets. Please go ahead.
Kemp Dolliver: Hi, thank you. Just quickly, and I know you are reluctant to give specific guidance, but with regard to your spending this year, how should we think about it relative to 2022? And that would be for all three expense buckets.
Eyal Shamir: Ronen?
Ronen Tsimerman: Okay. So, Eyal, would you like me to take the answer? Okay. So, we are expecting that 2023 will be quite similar to 2022. If you will look at the numbers, you will see that we are investing more in R&D and all the regulatory affairs and clinical affairs and also in the marketing. So, from all these aspects, you can expect to see probably the same numbers. We are planning to spend a little bit more on marketing, especially in the US.
Kemp Dolliver: Great. Thank you.
Operator: The next question is from Yi Chen of H.C. Wainwright. Please go ahead.
Chaitanya G.: Hey, this is Chait again on behalf of Yi. Just a quick follow up. I know I’ve seen that you’ve presented interim study results at the Urological Association Conference in Israel. And please bear with me if you have already touched upon this in your earlier calls, but what was the feedback from the physician community at that conference with regards to the data that you’ve presented?
Eyal Shamir: I would like to be sure that you refer to the kidney conference interim study that we published on December. This is what?
Chaitanya G.: Yes.
Eyal Shamir: Okay. So, the feedback that we got from the conference itself and with other KOL and physicians that we share this information in some of the events that we exhibited, like on February in the interventional radiology meeting in India, and January, it was the society interventional oncology in Washington, D.C., they believe that the results are very good, and they see the benefits of using one probe instead of multi-probe system. In one probe, which is less costly than two to three probes, that this is how they use when they work with Galil Medical and endocrine, argon and helium cryoablation technology. So, from the results of complication, navigation time, costing, the three probes cost much more. And the reimbursement, for example, in the US, it is same amount if you buy one probe or three probes from the results.
